For the quarter ending 2025-09-30, ACAD made $278,633K in revenue. $71,779K in net income. Net profit margin of 25.76%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 278,633 | 264,566 | 244,317 | 235,799 |
| Cost of product sales | 21,647 | 20,734 | 20,392 | 20,995 |
| Research and development | 87,829 | 77,951 | 78,265 | 78,881 |
| Gain on sale of non-financial asset | - | - | - | 24,419 |
| Selling, general and administrative | 133,401 | 133,507 | 126,370 | 118,378 |
| Total operating expenses | 242,877 | 232,192 | 225,027 | 169,415 |
| Income from operations | 35,756 | 32,374 | 19,290 | 66,383 |
| Interest income, net | 8,246 | 7,243 | 7,901 | 6,291 |
| Other income | 593 | 594 | 588 | 416 |
| Income before income taxes | 44,595 | 40,211 | 27,779 | 73,090 |
| Income tax expense (benefit) | -27,184 | 13,545 | 8,792 | 8,528 |
| Net loss | 71,779 | 26,666 | 18,987 | 64,562 |
| Diluted | 0.42 | 0.16 | 0.11 | 0.387 |
| Earnings per share, basic, total | 0.43 | 0.16 | 0.11 | 0.39 |
| Weighted average common shares outstanding, basic | 168,836,000 | 167,827,000 | 166,808,000 | -85,666.667 |
| Weighted average common shares outstanding, diluted | 170,650,000 | 168,681,000 | 167,668,000 | 61,333.333 |
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA PHARMACEUTICALS INC (ACAD)